BenevolentAI is Putting AI to Work to Treat Parkinson's Disease in the UK

The artificial intelligence company BenevolentAI is collaborating with two UK charities to use AI to identify ideal drug candidates for treating Parkinson's disease. BenevolentAI, Europe's largest private AI company, is collaborating with Parkinson's UK and The Cure Parkinson's Trust (CPT), two UK charities, to repurpose at least three existing drugs and identify two novel drug targets to treat Parkinson's disease. The collaboration underscores the growing use and multiple applications of AI in drug discovery. BenevolentAI's software uses a computational method known as a five-layer neural network to develop models that can predict the blood-brain barrier penetration and other properties of potential drug candidates. The software's judgment is continuously updated and improved using machine learning algorithms and feedback from experienced biomedical users.